IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma
IK-175, alone and with nivolumab, demonstrated a favorable safety profile, evidence of target engagement, and preliminary clinical activity in immune-refractory urothelial carcinoma. These data support continued development of AHR inhibitors to overcome adaptive immune resistance in solid tumors.
Authors
- Nerymar Ortiz-Otero (ORCID: https://orcid.org/0009-0000-2522-3030)
- Meredith McKean (ORCID: https://orcid.org/0000-0003-0944-7418)
- Nehal J. Lakhani (ORCID: https://orcid.org/0009-0005-6327-0176)
- Omar Alhalabi (ORCID: https://orcid.org/0000-0002-9658-2206)
- Wilmin Bartolini (ORCID: https://orcid.org/0009-0007-4496-5508)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Trupti Lingaraj (ORCID: https://orcid.org/0009-0004-9509-3437)
- I. Alex Bowman (ORCID: https://orcid.org/0000-0003-0323-7049)
- Jason J. Luke (ORCID: https://orcid.org/0000-0002-1182-4908)
- David H. Aggen (ORCID: https://orcid.org/0000-0003-3963-5751)
- Babar Bashir (ORCID: https://orcid.org/0000-0002-6843-1179)
- Sergio Santillana (ORCID: https://orcid.org/0000-0003-0076-7191)
- Marissa Timothy (ORCID: https://orcid.org/0000-0001-9257-2388)
- Elizabeth A. Guancial (ORCID: https://orcid.org/0000-0002-6518-5179)
- Katherine Kacena (ORCID: https://orcid.org/0000-0002-2038-692X)
- Katherine Kim (ORCID: https://orcid.org/0009-0002-8924-9496)
- Alan Tan (ORCID: https://orcid.org/0000-0002-6350-5917)
Institutions
- Rush University Medical Center (US)
- Boston Medical Center (US)
- Ciena (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Thomas Jefferson University (US)
- University of Pittsburgh (US)
- Vanderbilt University (US)
- Columbia University Irving Medical Center (US)
- Johns Hopkins Medicine (US)
- University of Rochester Medical Center (US)
- Midwest University (US)
- Sarah Cannon (US)
- Sidney Kimmel Cancer Center (US)
- Florida Cancer Specialists & Research Institute (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Tennessee Oncology (US)
- Healthy Start (US)
- Kura Oncology (United States) (US)
- International Organisation for Knowledge Economy and Enterprise Development (SE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Banner MD Anderson Cancer Center
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2013
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00